Clinical trials: Interstitial Cystitis/Bladder Pain Syndrome
- Condition Interstitial Cystitis/Bladder Pain Syndrome
- Funder type Industry (pharma, biotech, devices)
Cystitis, Interstitial
An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis
The purpose of this study is to determine whether PF-04383119 is effective in the treatment of pain associated with interstitial cystitis.
- Trial name
- NCT00601484
- Testing
- PF-04383119
- Where
- 34 sites in United States
- Volunteers
- 65 people
- Sponsor
- Pfizer
Interstitial Cystitis
Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome
The purpose of this study is to assess the safety and tolerability of two doses of LP08 compared to placebo. Hypothesis: Safety of the LP-08 therapy will not be significantly different from the placebo group.
- Trial name
- NCT01393223
- Testing
- LP-08 80mg, Normal saline, LP-08 20mg
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Lipella Pharmaceuticals, Inc.
Interstitial Cystitis
A Study to Test if Fremanezumab Reduces Pain in Patients With Interstitial Cystitis-Bladder Pain Syndrome
The primary objective of the study is to evaluate the efficacy of fremanezumab in reducing pain in patients with interstitial cystitis-bladder pain syndrome (IC-BPS).
- Trial name
- NCT04447729
- Testing
- fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Cystitis, Interstitial
A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome
In a previous study in patients with interstitial cystitis/ painful bladder syndrome (IC/PBS), tanezumab has shown to be efficacious in relieving the pain associated with IC/PBS, as well as some effect on reducing urinary…
- Trial name
- NCT00999518
- Testing
- Tanezumab
- Where
- 171 sites in United States, Belgium and 12 more
- Volunteers
- 205 people
- Sponsor
- Pfizer
Interstitial Cystitis
Safety Study of Single Intravesical Doses of TTI-1612 in Women With Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to determine the safety and pharmacokinetics of TTI-1612 in women with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT01559961
- Testing
- TTI-1612
- Where
- 4 sites in Canada
- Volunteers
- 28 people
- Sponsor
- Trillium Therapeutics Inc.
Cystitis, Interstitial, Painful Bladder Syndrome
A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome
This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.
- Trial name
- NCT02411110
- Testing
- LiRIS®
- Where
- 34 sites in United States, Canada
- Volunteers
- 131 people
- Sponsor
- Allergan
Interstitial Cystitis, Bladder Pain Syndrome
Assessment of Urinary Polymerase Chain Reaction (PCR) and Next Generation Sequencing (NGS) Technology in the Evaluation and Management of Females With Chronic Bladder Pain and Cystitis-like Symptoms
Real-world clinical practice multicenter study to determine the clinical implications of employing PCR/NGS technology to identify and treat potential urinary pathogens in female participants identified with bladder pain and/or…
- Trial name
- NCT05276466
- Testing
- Polymerase Chain Reaction and Next-Generation DNA Sequencing
- Where
- 4 sites in United States
- Volunteers
- 100 people
- Sponsor
- MicroGenDX
Cystitis, Interstitial, Urologic Diseases
A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain
The purpose of this study is to evaluate the analgesic efficacy, safety, and tolerability of JNJ-42160443 compared to placebo in patients with moderate to severe, chronic bladder pain from interstitial cystitis and/or painful…
- Conditions
- Cystitis, Interstitial, Urologic Diseases, Urinary Bladder Diseases, Cystitis
- Trial name
- NCT01060254
- Testing
- JNJ-42160443
- Where
- 25 sites in United States, Canada
- Volunteers
- 31 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome
This study evaluates the effects of two doses of oral AQX-1125 on bladder pain and other urinary symptoms in subjects with interstitial cystitis/bladder pain syndrome.
- Conditions
- Interstitial Cystitis, Bladder Pain Syndrome, Painful Bladder Syndrome, Chronic Interstitial Cystitis
- Trial name
- LEADERSHIP 301 (NCT02858453)
- Testing
- AQX-1125 100 mg, AQX-1125 200 mg
- Where
- 120 sites in United States, Belgium and 10 more
- Volunteers
- 433 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Bladder Pain Syndrome, Interstitial Cystitis
A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis
The purpose of this study is to investigate efficacy, safety and tolerability of ASP6294 in female participants with Bladder Pain Syndrome/Interstitial Cystitis (BPS/IC).
- Trial name
- SERENITY (NCT03282318)
- Testing
- ASP6294
- Where
- 28 sites in Belgium, Czechia and 8 more
- Volunteers
- 119 people
- Sponsor
- Astellas Pharma Europe B.V.
Interstitial Cystitis, Bladder Pain Syndrome
PK and Safety of SI-722 in IC/BPS
This study is designed randomized, double-blind, placebo-controlled trial in Interstitial Cystitis/Bladder Pain Syndrome patients.
- Trial name
- NCT04208087
- Testing
- SI-722
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Seikagaku Corporation
Interstitial Cystitis, Bladder Pain Syndrome
A Phase 2 Study of IW-3300 for the Treatment of Bladder Pain in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
The aim of this study is to assess whether IW-3300 is safe and works for the treatment of interstitial cystitis/bladder pain syndrome (IC/BPS).
- Trial name
- NCT05740007
- Testing
- IW-3300 rectal foam
- Where
- 53 sites in United States
- Volunteers
- 98 people
- Sponsor
- Ironwood Pharmaceuticals, Inc.
Painful Bladder Syndrome, Interstitial Cystitis
Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis
A double-blind, placebo-controlled study to evaluate changes in pain, urgency and urinary frequency following administration of URG101 compared to placebo.
- Conditions
- Painful Bladder Syndrome, Interstitial Cystitis, Bladder Pain Syndrome
- Trial name
- NCT00517868
- Testing
- URG101
- Where
- 6 sites in United States
- Volunteers
- 28 people
- Sponsor
- Urigen
Interstitial Cystitis, IC
Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients
The investigators believe that this study is of importance of several aspects: 1. It evaluates a new mode of bladder instillation that may bypass the drawbacks of the current instillation mode. 2.
- Trial name
- NCT01997983
- Testing
- TC-3 Gel mixed with Botox (BTX)
- Where
- Israel
- Volunteers
- 15 people
- Sponsor
- UroGen Pharma Ltd.
Cystitis, Interstitial
Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis
This study will explore the safety and effectiveness of different doses of AGN 203818 in treating the pain associated with painful bladder syndrome/interstitial cystitis
- Trial name
- NCT00380783
- Testing
- AGN 203818
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Allergan
Interstitial Cystitis/Bladder Pain Syndrome
Study of V117957 in Interstitial Cystitis/Bladder Pain Syndrome
The purpose of this study is to evaluate the safety, tolerability and efficacy of V117957 in subjects with interstitial cystitis/bladder pain syndrome, compared to placebo.
- Trial name
- NCT06285214
- Testing
- V117957
- Where
- 24 sites in United States
- Volunteers
- 47 people
- Sponsor
- Imbrium Therapeutics
Interstitial Cystitis, Bladder Pain Syndrome
Efficacy and Safety of AQX-1125 in IC/BPS
The primary objective of this study is to evaluate the effect of 6 weeks of treatment with once daily administration of AQX-1125 compared to placebo on average daily pain in subjects with interstitial cystitis/bladder pain…
- Trial name
- LEADERSHIP (NCT01882543)
- Testing
- AQX-1125
- Where
- 29 sites in United States, Canada
- Volunteers
- 69 people
- Sponsor
- Aquinox Pharmaceuticals (Canada) Inc.
Interstitial Cystitis, Painful Bladder Syndrome
OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS)
The study compares the analgesic efficacy of OXN PR vs placebo in opioid-naive subjects suffering from severe pain due to Bladder Pain Syndrome.
- Conditions
- Interstitial Cystitis, Painful Bladder Syndrome, Pain
- Trial name
- NCT01197261
- Testing
- Oxycodone naloxone prolonged release tablets
- Where
- 5 sites in Czechia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Mundipharma Research GmbH & Co KG
Interstitial Cystitis
A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome.
This is a pilot clinical investigation. Patients who meet the eligibility criteria and provide signed informed consent will be randomized to receive either an active product (Uracyst®) or placebo intravesically via a bladder…
- Trial name
- NCT00527917
- Testing
- Uracyst
- Where
- 13 sites in Canada
- Volunteers
- 65 people
- Sponsor
- Watson Pharmaceuticals
Interstitial Cystitis, Painful Bladder Syndrome
Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome
A new device for interstitial cystitis is compared to inactive control to determine if it is safe and effective. The study lasts approximately 7 weeks with a 19-week follow-up period.
- Trial name
- NCT00919113
- Testing
- 2% sodium chondroitin sulfate
- Where
- 20 sites in United States
- Volunteers
- 98 people
- Sponsor
- Watson Pharmaceuticals